Neurophth Therapeutics Raises USD60M in Series C Funding
Neurophth Therapeutics, a Wuhan, Shanghai, and Suzhou, China- and San Diego CA-based integrated genomic medicines company, raised USD60M in Series C funding. Additional new investors include funds and accounts managed by Sunshine Insurance and China Merchant Bank International Capital. Led by Alvin Luk, CEO, Neurophth is a gene therapy company for ophthalmic diseases. The pipeline also includes ND1-mediated LHON, autosomal dominant optic atrophy, optic neuroprotection (e.g., glaucoma), vascular retinopathy (e.g., diabetic retinopathy), and five other preclinical candidates. Neurophth has initiated the scaling up in-house manufacturing process in single-use technologies to support future commercial demand at the Suzhou facilities.